Side effects of drugs annual: a worldwide yearly survey of new data in adverse drug reactions, first edition. Ray SD, Gray JP, Kiersma ME, Dukes MNG, eds. Waltham, MA: Elsevier, 2015 Nov; 37:329-348
Topical cidofovir treatment in herpes simples virus infections resulted in irreversible acute kidney injury. A 58-year-old man underwent a matched unrelated donor (MUD) stem cell transplant for secondary myelodysplastic syndrome. His conditioning regimen consisted of busulfan, fludarabine, and antithymocyte globulin. The patient received oral valganciclovir during the peritransplantation phase at a dose of 900 mg twice daily for CMV prophylaxis, and prophylactic valacyclovir was initiated on day 1. The patient was readmitted within 2 weeks of his initial hospital discharge with neutropenic fever, worsening mucositis, and acute cutaneous graft-versushost disease (GVHD). The patient was treated with intravenous (IV) acyclovir at 5 mg/kg followed by antiviral therapy containing 5% cidofovir administered as oral gel.
Sreekumar Othumpangat, Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, WV 26505
CODEN
SEDAD8
Publication Date
20151113
Document Type
Chapter
Email Address
seo8@cdc.gov
Editors
Ray SD; Gray JP; Kiersma ME; Dukes MNG
Fiscal Year
2016
ISBN No.
9780444635259
ISSN
0378-6080
NIOSH Division
HELD
Priority Area
Healthcare and Social Assistance
Source Name
Side effects of drugs annual: a worldwide yearly survey of new data in adverse drug reactions, first edition
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.